MDSpire - Takeaway
FDA & Government News

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Share

  • 1

    Orforglipron is FDA approved for chronic weight management.

  • 2

    It is taken once daily as an oral GLP-1 receptor agonist.

  • 3

    Significant mean weight loss observed: 27.3 lbs with high dose.

  • 4

    Reduces cardiometabolic risk markers.

  • 5

    Safety warning for thyroid tumors; not for certain patient histories.

  • 6

    Available via LillyDirect starting April 6,

  • 7

    Pricing options available for patients, including a savings program.

Original Source(s)

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

  • by Kathryn Wighton

  • April 1, 2026

Related Content

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min
Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens

Your Biological Age? It's in the Blood

Multi-marker model may refine risk prediction and preventive testing

  • April 1, 2026

  • 2 min